03681.HK
SinoMab BioScience Limited
HKSE · Healthcare · Biotechnology · HK
HKD 1.15
+0.88%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.7M | — | 2.0M | 1.4M | 4.0M |
| Cost of Revenue | — | 26.6M | 1.5M | 943.0K | — |
| Gross Profit | 5.7M | (26.6M) | 543.0K | 422.0K | 4.0M |
| Operating Expenses | |||||
| R&D Expense | 170.9M | 79.5M | 94.8M | 135.4M | 180.4M |
| SG&A Expense | 119.0M | 46.4M | 67.7M | 97.6M | 82.6M |
| General & Admin Expense | 79.9M | 46.4M | 67.7M | 97.4M | 82.4M |
| Selling & Marketing Expense | — | — | — | 174.0K | 164.0K |
| Other Expenses | (377.9K) | (27.8M) | (571.0K) | (3.0M) | — |
| Total Operating Expenses | 289.5M | 98.1M | 161.9M | 230.0M | 263.0M |
| Cost and Expenses | 289.5M | 124.7M | 163.4M | 230.9M | 263.0M |
| Operating Income (EBIT) | (293.5M) | (124.7M) | (161.4M) | (229.6M) | (258.9M) |
| Non-Operating | |||||
| Interest Income | 507.0K | 3.6M | 5.9M | 6.2M | 4.6M |
| Interest Expense | 8.8M | 5.4M | 8.7M | 6.6M | — |
| Net Interest Income | (8.3M) | (1.8M) | (2.8M) | (408.0K) | 4.6M |
| Other Non-Op Income/Expense | (32.6M) | 22.4M | (23.8M) | (13.5M) | (25.2M) |
| Non-Operating Income (excl Interest) | — | — | 571.0K | 7.0M | — |
| EBT (Pre-Tax Income) | (326.1M) | (102.3M) | (185.1M) | (243.1M) | (284.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (326.1M) | (102.3M) | (185.1M) | (243.1M) | (284.2M) |
| Earnings from Cont. Ops | (326.1M) | (102.3M) | (185.1M) | (243.1M) | (284.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (326.1M) | (102.3M) | (185.1M) | (243.1M) | (284.2M) |
| Per Share | |||||
| Basic EPS | (HK$0.27) | (HK$0.08) | (HK$0.17) | (HK$0.24) | (HK$0.29) |
| Diluted EPS | (HK$0.27) | (HK$0.08) | (HK$0.17) | (HK$0.24) | (HK$0.29) |
| Revenue Per Share | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.4B | 1.2B | 1.1B | 1.0B | 992.0M |
| Diluted Shares Outstanding | 1.4B | 1.2B | 1.1B | 1.0B | 992.0M |
| Profitability Metrics | |||||
| EBITDA | (276.5M) | (72.1M) | (142.8M) | (200.5M) | (244.3M) |
| D&A | 36.9M | 27.3M | 19.1M | 36.1M | 14.6M |
| EBIT | (293.5M) | (124.7M) | (161.9M) | (236.5M) | (258.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026